

Xenopsin-Related Peptide 2

| | |
|----------------------|---|
| Cat. No.: | HY-P3837 |
| CAS No.: | 117442-29-2 |
| Molecular Formula: | C ₆₀ H ₈₈ N ₁₆ O ₁₀ |
| Molecular Weight: | 1193.44 |
| Sequence Shortening: | FHPKRPWIL |
| Target: | Others |
| Pathway: | Others |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | | | | | | | | | |
|--------------------|--|---------------|--|---------|-------------|-----------------|------------------------------|---------|--|
| Description | Xenopsin-Related Peptide 2 (XP-2) is an avian counterpart to amphibian Xenopsin (HY-P0253). Xenopsin-Related Peptide 2 displays abilities to release histamine from isolated rat mast cells and is as effective as synthetic Bradykinin (HY-P0206) ^[1] . | | | | | | | | |
| In Vitro | Synthetic and native preparations of Xenopsin-Related Peptide 2 (XP-2) increases vascular permeability in rats and released histamine from isolated rat mast cells at submicromolar concentrations ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | | | | | | | |
| In Vivo | Xenopsin-Related Peptide 2 (XP-2) (0.3-3000 nM; intradermally; 50 µL) induces skin vascular permeability in rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | | | | | | | |
| | <table> <tr> <td>Animal Model:</td> <td>Rats weighing 300-400 g^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.3-3000 nM</td> </tr> <tr> <td>Administration:</td> <td>Intradermal injection, 50 µL</td> </tr> <tr> <td>Result:</td> <td>Increased skin vascular permeability in a dose-dependent manner.</td> </tr> </table> | Animal Model: | Rats weighing 300-400 g ^[1] | Dosage: | 0.3-3000 nM | Administration: | Intradermal injection, 50 µL | Result: | Increased skin vascular permeability in a dose-dependent manner. |
| Animal Model: | Rats weighing 300-400 g ^[1] | | | | | | | | |
| Dosage: | 0.3-3000 nM | | | | | | | | |
| Administration: | Intradermal injection, 50 µL | | | | | | | | |
| Result: | Increased skin vascular permeability in a dose-dependent manner. | | | | | | | | |

REFERENCES

[1]. Carraway RE, et al. Xenopsin-related peptide generated in avian gastric extracts. Regul Pept. 1988 Sep;22(4):303-14.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA